The latest happenings of the past month in the industry, all in one place.
Jennifer Rogers
PHASTAR announced that Jennifer Rogers, PhD, has been appointed Head of Statistical Research.
PHASTAR also announced that Jennifer Bradford, PhD, has been named to lead PHASTAR’s Data Science Group.
Signant Health, formerly CRF Health and Bracket, has appointed Anthony Todd Everhart, to the Signant Health Science and Medicine Team as Clinical Vice President, Internal Medicine.
Anthony Todd Everhart
The Society for Clinical Research Sites announced that Clinithink has joined the organization as a Global Impact Partner.
CROMSOURCE has opened a newly expanded office in Cary, NC.
ERT has announced its sponsorship of the 2019 Simon’s Heart “Protect This Heart” student fall screening program.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.